News

Maxigesic IV® distribution deals signed in UK and Hong Kong

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) has signed exclusive Maxigesic IV® distribution and supply agreements for the UK and Hong Kong, with the company targeting sales of the medicine in these territories in 2022.

Read More

Kiwi Health Flagship Store Launches in China on Tmall Global

ASX-listed RooLife (ASX:RLG) and ASX and NZX-listed AFT Pharmaceuticals (ASX:AFP, NZX:AFT) have officially launched the New Zealand branded online health and pharmacy store in China – “Kiwi Health”

Read More

AFT Pharmaceuticals to announce half year interim results on Thursday November 19 2020

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release on Thursday November 19 2020 its half year interim results for the period ended September 30 2020. The release will be issued at around 09:00.

Read More

Notice of Adjourned Annual Meeting of Shareholders 2020

Notice is hereby given that the adjourned Annual Meeting of shareholders of AFT Pharmaceuticals Limited (AFT or the Company) will be convened and held on a fully virtual basis on Tuesday, 8 September 2020 commencing at 10.30am (New Zealand time) to transact the business set out in the Notice of Annual Meeting of Shareholders 2020 dated 15 July 2020 (Original AGM Notice).

Read More

Urgent Adjournment of 2020 Annual Meeting

AFT Pharmaceuticals Limited (NZX:AFT/ASX:AFP) (AFT) advises that the Annual Meeting of shareholders of AFT scheduled for 10.30am (NZ time) today will be adjourned to a time and date to be advised. This follows the Government’s announcement that the Auckland Region will move to COVID-19 alert level 3 today, which means that shareholders should stay home and refrain from attending the meeting.

Read More

Maxigesic IV® licensed in six new European nations

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) has signed an exclusive Maxigesic IV® licensing and supply agreement for Bulgaria, Cyprus, the Czech Republic, Hungary, Romania and Slovakia, countries with a combined population of more than 53 million*.

Read More

New Zealand codeine restrictions set for November

AFT Pharmaceuticals (NZX:AFT, ASX:AFT) today welcomes Medsafe’s announcement that all codeine and codeine-containing medicines will become prescription only from 5 November 2020.

Read More

Notice of Annual Meeting of Shareholders 2020

Notice is hereby given that the Annual Meeting of shareholders of AFT Pharmaceuticals Limited (*AFT or the Company*) will be held at the Milford Cruising Club, 24 Craig Road, Milford, Auckland, New Zealand, on *Wednesday, 12 August 2020 commencing at 10.30am* (New Zealand time).

Read More

RooLife & AFT launch Online New Zealand Health Store in China

RooLife partners with ASX & NZX-listed AFT Pharmaceuticals (ASX:AFP, NZX:AFT) to deliver New Zealand branded online health & pharmacy store in China

Read More

AFT Pharmaceuticals Share Purchase Plan Oversubscribed

AFT Pharmaceuticals Limited (NZX:AFT/ASX:AFP) (AFT) is pleased to announce that its NZ$2 million share purchase plan (SPP) has closed oversubscribed. The SPP received strong shareholder support with AFT receiving applications totalling approximately NZ$9.8 million. Applications will be scaled on a proportionate basis in accordance with the number of AFT shares held by applicants on the SPP record date (9 June 2020). Refunds of surplus application amounts paid will be made to applicants in accordance with the terms of the SPP offer document.

Read More

Nathan Hukill resigns from AFT’S Board

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces Nathan Hukill, president of the company’s former major shareholder CRG, has resigned as a non-executive director of AFT.

Read More

AFT Pharmaceuticals announces opening of Share Purchase Plan

AFT Pharmaceuticals Limited (NZX:AFT/ASX:AFP) (AFT) is pleased to announce the opening of its NZ$2 million non-underwritten share purchase plan (SPP). The SPP is part of AFT Pharmaceuticals’ capital raising announced on 10 June 2020, whereby AFT also undertook a fully underwritten NZ$10 million placement of new shares to select investors in both local and offshore markets and certain major shareholders sold down NZ$63.8 million of existing shares (together, the Placement). AFT announced the successful completion of the Placement on 11 June 2020, which was strongly supported and fully subscribed at a price of NZ$3.75 per share.

Read More